HealthCor Catalio Acquisition Corp. (HCAQ): Price and Financial Metrics
HCAQ Price/Volume Stats
|Current price||$10.92||52-week high||$11.00|
|Prev. close||$10.43||52-week low||$9.48|
|Day high||$10.93||Avg. volume||114,974|
|50-day MA||$9.98||Dividend yield||N/A|
|200-day MA||$9.93||Market Cap||232.75M|
HCAQ Stock Price Chart Interactive Chart >
HealthCor Catalio Acquisition Corp. (HCAQ) Company Bio
HealthCor Catalio Acquisition Corp. operates as a blank check company. The Company aims to acquire one and more businesses and assets, via a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization.
HCAQ Latest News Stream
|Loading, please wait...|
HCAQ Latest Social Stream
View Full HCAQ Social Stream
Latest HCAQ News From Around the Web
Below are the latest news stories about HealthCor Catalio Acquisition Corp that investors may wish to consider to help them evaluate HCAQ as an investment opportunity.
Hyperfine Closes Business Combination with HealthCor Catalio Acquisition Corp and Liminal Sciences, Will Begin Trading under the Ticker "HYPR" on the Nasdaq Global Market
Hyperfine Inc., the groundbreaking medical device company that created Swoop®, the world's first FDA-cleared portable MRI system™, today announced that it has completed its business combination with HealthCor Catalio Acquisition Corp. (Nasdaq: HCAQ) ("HealthCor"), a special purpose acquisition company sponsored by leading healthcare funds HealthCor Management, L.P. and Catalio Capital Management, LP, and Liminal Sciences, Inc. ("Liminal"), a medical device development company dedicated to non-in
HealthCor Catalio Acquisition Corp. Reminds Shareholders to Vote in Favor of the Business Combination with Hyperfine, Inc. and Liminal Sciences, Inc.
HealthCor Catalio Acquisition Corp. (Nasdaq: HCAQ) ("HealthCor") reminds its shareholders to vote at the upcoming extraordinary general meeting of HealthCor's shareholders (the "Special Meeting") on December 21, 2021 to, among other matters, approve the proposed business combination with Hyperfine, Inc. ("Hyperfine") and Liminal Sciences, Inc. ("Liminal") and, in connection therewith, HealthCor's change of domicile to Delaware (the "Domestication").
Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies:
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of HealthCor Catalio Acquisition Corp. (Nasdaq - HCAQ)
BALA CYNWYD, PA / ACCESSWIRE / July 8, 2021 / Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of HealthCor Catalio Acquisition Corp. ("HealthCor Catalio" or the "Company") (Nasdaq - HCAQ) for possible breaches of fiduciary duty and other violations of federal and state law in connection with a merger agreement pursuant to which HealthCor Catalio, a special purpose acquisition company, will combine with Hyperfine, Inc.
Hyperfine, Inc., Creator of the First FDA-Cleared Portable MRI Device, and Liminal Sciences, Inc. To Be Listed on Nasdaq Through a Business Combination With HealthCor Catalio Acquisition Corp.
GUILFORD, Conn., July 08, 2021--Hyperfine, Inc. and Liminal Sciences, Inc. to be listed on Nasdaq through a business combination with HealthCor Catalio Acquisition Corp.
HCAQ Price Returns